The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Open accessAbstract
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Edoxaban 60 mg once daily was non-inferior to warfarin (primary outcome, HR 0.87; 97.5% CI 0.73-1.04;P = 0.08).”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
In the citing paper
“while edoxaban 30 mg once daily was non-inferior to warfarin for prevention of stroke and systemic embolism but significantly reduced major bleeding events by 53%.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
In the citing paper
“In an on-treatment analysis, edoxaban 60 mg once daily significantly reduced stroke or systemic embolism by 21% and significantly reduced major bleeding events by 20% compared with warfarin”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
In the citing paper
“Renal clearance”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Self-citationEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Flagged first, then by citations
Research works printed but not linked: 1
- Grip LT, 2013, Hot Topics Cardiol, 31, 7
Cited by
Sorted by citations
Items 701–800 of 1,005
Higher heart rate variability as a predictor of atrial fibrillation in patients with hypertension
Kim, S. H., Lim, K. R., Seo, J., Ryu, D., Lee, B., Cho, B. R., & Chun, K. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-07783-3 · Cited by 47
Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation
Ruff, C. T., Giugliano, R. P., Braunwald, E., Mercuri, M. F., Curt, V., Betcher, J., Grip, L. T., Cange, A. L., Crompton, A. E., Murphy, S. A., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.028 · Cited by 48
Ko, D., Cove, C. L., & Hylek, E. M. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-12-1032 · Cited by 46
Morimoto, T., Crawford, B., Wada, K., & Ueda, S. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.05.018 · Cited by 46
O’Donoghue, M. L., Ruff, C. T., Giugliano, R. P., Murphy, S. A., Grip, L. T., Mercuri, M. F., Rutman, H., Shi, M., Kania, G., Čermák, O., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv014 · Cited by 46
Heidbüchel, H., Berti, D., Campos, M., Desteghe, L., Freixo, A. P., Nunes, A. R., Roldán, V., Toschi, V., & Lassila, R. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0046-0 · Cited by 46
Ito, M., Kaikita, K., Sueta, D., Ishii, M., Oimatsu, Y., Arima, Y., Iwashita, S., Takahashi, A., Hoshiyama, T., Kanazawa, H., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002744 · Cited by 46
Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure
Raccah, B. H., Perlman, A., Danenberg, H. D., Pollak, A., Muszkat, M., & Matok, I. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.12.029 · Cited by 47
Annoni, G., & Mazzola, P. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.03.010 · Cited by 46
Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice
Mazurek, M., Huisman, M. V., & Lip, G. Y. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.09.012 · Cited by 46
Clarkesmith, D. E., Lip, G. Y. H., & Lane, D. A. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.03.002 · Cited by 46
Interventional and surgical occlusion of the left atrial appendage
Caliskan, E., Cox, J. L., Holmes, D. R., Meier, B., Lakkireddy, D., Falk, V., Salzberg, S. P., & Emmert, M. Y. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.107 · Cited by 45
Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature
Shaw, J. R., & Siegal, D. M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12089 · Cited by 46
Reddy, V. Y., Akehurst, R. L., Gavaghan, M. B., Amorosi, S. L., & Holmes, D. R. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011577 · Cited by 46
Boriani, G., Blomström‐Lundqvist, C., Hohnloser, S. H., Bergfeldt, L., Botto, G. L., Capucci, A., Lozano, I. F., Goette, A., Israel, C. W., Merino, J. L., et al. (2019) · EP Europace · doi:10.1093/europace/euz193 · Cited by 46
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
Bergmark, B. A., Kamphuisen, P. W., Wiviott, S. D., Ruff, C. T., Antman, E. M., Nordio, F., Kuder, J., Mercuri, M. F., Lanz, H., Braunwald, E., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041346 · Cited by 47
Dalgaard, F., Mulder, H. S., WOJDYLA, D. M., Lópes, R. D., Held, C., Alexander, J. H., Caterina, R. D., Washam, J. B., Hylek, E. M., Garcia, D. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041296 · Cited by 46
Lee, K., Choi, J., Boo, K. Y., Kim, D. Y., Kim, Y. G., Oh, S., Baek, Y., Lee, D. I., Roh, S., Shim, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58665-5 · Cited by 46
Kohsaka, S., Katada, J., Saito, K., Jenkins, A. K., Li, B. H., Mardekian, J., & Terayama, Y. (2020) · Open Heart · doi:10.1136/openhrt-2019-001232 · Cited by 46
Paschke, L. M., Klimke, K., Altiner, A., von Stillfried, D., & Schulz, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01695-7 · Cited by 50
“Edoxaban showed lower IR for mortality while the pivotal study found no difference in risk [5].”
BackgroundResultHanon, O., Vidal, J., Pisica–Donose, G., Orvoën, G., David, J., Chaussade, E., Caillard, L. K., de Jong, L. W., Boulloche, N., Vinsonneau, U., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-317923 · Cited by 47
Alzheimer’s disease: the impact of age-related changes in reproductive hormones
Bates, K., Harvey, A. R., Carruthers, M., & Martins, R. N. (2005) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-004-4383-1 · Cited by 47
Radionuclide imaging of nonosseous infection.
Palestro, C. J., & Torres, M. A. (1999) · PubMed · Cited by 46
Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis
Riaz, I. B., Fuentes, H. E., Deng, Y., Naqvi, S. A. A., Yao, X., Sangaralingham, L. R., Houghton, D. E., Padrnos, L. J., Shamoun, F. E., Wysokiński, W. E., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.25283 · Cited by 45
Douxfils, J., Tamigniau, A., Châtelain, B., Goffinet, C., Dogné, J.-M., & Mullier, F. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-24 · Cited by 47
Pilotto, A., Gallina, P., Copetti, M., Pilotto, A., Marcato, F., Mello, A. M., Simonato, M., Logroscino, G., Padovani, A., Ferrucci, L., et al. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14221 · Cited by 46
Vandell, A. G., Lee, J., Shi, M., Rubets, I., Brown, K. S., & Walker, J. R. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.82 · Cited by 45
Abe, M., Ogawa, H., Ishii, M., Masunaga, N., Esato, M., Chun, Y., Tsuji, H., Wada, H., Hasegawa, K., Lip, G. Y. H., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.01.005 · Cited by 47
Pannach, S., Goetze, J., Marten, S., Schreier, T., Tittl, L., & Beyer‐Westendorf, J. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1320-7 · Cited by 45
Adcock, D. M., & Gosselin, R. C. (2017) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12658 · Cited by 45
Attena, E., Mazzone, C., Esposito, F., Parisi, V., Bancone, C., Rago, A., Nigro, G., Sangiuolo, R., D’Onofrio, A., & Russo, V. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1615261 · Cited by 45
Miklič, M., Mavri, A., Vene, N., Söderblom, L., Mijovski, M. B., Pohanka, A., Antović, J. P., & Malmström, R. E. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02693-2 · Cited by 47
Altiok, E., & Marx, N. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0776 · Cited by 47
Cho, M. S., Yun, J. E., Park, J. J., Kim, Y. J., Lee, J., Kim, H., Park, D., & Nam, G. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.01.044 · Cited by 45
Guo, J., Ma, X., Skidmore, J. M., Cimerman, J., Prieskorn, D. M., Beyer, L. A., Swiderski, D. L., Dolan, D. F., Martin, D. M., & Raphael, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.009 · Cited by 45
Peri-procedural management of patients taking oral anticoagulants
Daniels, P. R. (2015) · BMJ · doi:10.1136/bmj.h2391 · Cited by 46
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants
Benamouzig, R., Guenoun, M., Deutsch, D., & Fauchier, L. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07211-0 · Cited by 49
Chinese guidelines for the diagnosis and management of atrial fibrillation
Ma, C., Wu, S., Liu, S., & Han, Y. (2024) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.14920 · Cited by 48
Fu, W., Guo, H., Guo, J., Lin, K., Wang, H., Zhang, Y., Wang, Y., & Shan, Z. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000206 · Cited by 44
Khairy, P., Hare, G. F. V., Balaji, S., Berul, C. I., Cecchin, F., Cohen, M. I., Daniels, C. J., Deal, B. J., Dearani, J. A., de Groot, N. M. S., et al. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.05.008 · Cited by 45
Caterina, R. D., & Camm, A. J. (2015) · EP Europace · doi:10.1093/europace/euv288 · Cited by 44
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism
Wells, P. S., Segers, A. E. M., Ageno, W., Brekelmans, M. P. A., Cohen, A. T., Meyer, G., GROSSO, M. A., Raskob, G., Weitz, J. I., Zhang, G., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0244 · Cited by 45
Allan, V., Banerjee, A., Shah, A. D., Patel, R. S., Denaxas, S., Casas, J. P., & Hemingway, H. (2016) · Heart · doi:10.1136/heartjnl-2016-309910 · Cited by 45
Direct Oral Anticoagulants in Emergency Trauma Admissions
Maegele, M., Grottke, O., Schöchl, H., Sakowitz, O. W., Spannagl, M., & Koscielny, J. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0575 · Cited by 45
Turagam, M. K., Lavu, M., Afzal, M. R., Vuddanda, V. L. K., Jazayeri, M., Parikh, V. K., Atkins, D., Bommana, S., Biase, L. D., Horton, R., et al. (2016) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.13148 · Cited by 45
Current challenges and future prospects in oral anticoagulant therapy
Czuprynska, J., Patel, J. P., & Arya, R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14714 · Cited by 43
Thorp, B. C., & Badoux, X. C. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1339874 · Cited by 44
Pikija, S., Sztriha, L., Mutzenbach, J. S., Golaszewski, S. M., & Sellner, J. (2017) · CNS Drugs · doi:10.1007/s40263-017-0460-x · Cited by 44
Novel oral anticoagulant use in adult Fontan patients: A single center experience
Georgekutty, J., Kazerouninia, A., Wang, Y., Ermis, P. R., Parekh, D. R., Franklin, W., & Lam, W. (2018) · Congenital Heart Disease · doi:10.1111/chd.12603 · Cited by 44
Aonuma, K., Yamasaki, H., Nakamura, M., Ootomo, T., Takayama, M., Andò, K., Hirao, K., Morino, Y., Hayashida, K., Kusano, K., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0222 · Cited by 44
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
Zeitouni, M., Giczewska, A., Lópes, R. D., WOJDYLA, D. M., Christersson, C., Siegbahn, A., Caterina, R. D., Steg, P. G., Granger, C. B., Wallentin, L. C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.060 · Cited by 43
Boriani, G., Ruff, C. T., Kuder, J., Shi, M., Lanz, H., Antman, E. M., D, E. B. M., & Giugliano, R. P. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1716540 · Cited by 44
Radadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 50
Ex vivo reversal of the anticoagulant effects of edoxaban
Halim, A., Samama, M. M., & Mendell, J. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.036 · Cited by 43
Managing reversal of direct oral anticoagulants in emergency situations
Buller, H. R., Falanga, A., Hacke, W., Hendriks, J., Lobban, T., Merino, J. L., Milojević, I., Moya, F., van der Worp, H. B., Randall, G., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0363 · Cited by 43
Deitelzweig, S. B., Keshishian, A. V., Kang, A. L., Dhamane, A. D., Luo, X., Balachander, N., Rosenblatt, L. C., Mardekian, J., Jiang, J. Z., Yüce, H., et al. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284821997352 · Cited by 43
JCS / JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Journal of Arrhythmia · doi:10.1002/joa3.12714 · Cited by 41
Kar, S., Doshi, S. K., Alkhouli, M. A., Camm, A. J., Coylewright, M. J., Gibson, C. M., Granger, C. B., Gurol, M. E., Huber, K., MANSOUR, M. C., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.05.022 · Cited by 43
Lauffenburger, J. C., Rhoney, D. H., Farley, J. F., Gehi, A. K., & Fang, G. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1597 · Cited by 43
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis
Petzold, T., Thienel, M., Konrad, I., Schubert, I., Regenauer, R., Hoppe, B. F., Lorenz, M. C., Eckart, A., Chandraratne, S., Lennerz, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6712 · Cited by 44
Yoshio, T., Tomida, H., Iwasaki, R., Horiuchi, Y., Omae, M., Ishiyama, A., Hirasawa, T., Yamamoto, Y., Tsuchida, T., Fujisaki, J., et al. (2017) · Digestive Endoscopy · doi:10.1111/den.12859 · Cited by 43
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation
Fanikos, J. R., Burnett, A., Mahan, C. E., & Dobesh, P. P. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.015 · Cited by 43
Åsberg, S., Hijazi, Z., Norrving, B., Terént, A., Öhagen, P., & Oldgren, J. (2017) · Trials · doi:10.1186/s13063-017-2313-9 · Cited by 43
Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Aronis, K. N., & Hylek, E. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007338 · Cited by 45
Yoshimura, S., Koga, M., Sato, S., Todo, K., Yamagami, H., Kumamoto, M., Itabashi, R., Terasaki, T., Kimura, K., Yagita, Y., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0067 · Cited by 43
Allison, T. A., Lin, P. J., Gass, J. A., Chong, K., Prater, S. J., Escobar, M. A., & Hartman, H. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618800657 · Cited by 43
Medium-Chain Acylcarnitines Are Associated With Cardioembolic Stroke and Stroke Recurrence
Seo, W., Jo, G., Shin, M., & Oh, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311373 · Cited by 41
GARFIELD-AF: A Worldwide Prospective Registry of Patients With Atrial Fibrillation at Risk of Stroke
Bassand, J., Apenteng, P. N., Atar, D., Camm, A. J., Cools, F. J. S., Corbalan, R. L., Fitzmaurice, D. A., Fox, K. A. A., Goto, S., Haas, S. K., et al. (2020) · Future Cardiology · doi:10.2217/fca-2020-0014 · Cited by 48
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source
Shoamanesh, A., Hart, R. G., Connolly, S. J., Kasner, S. E., Smith, E. E., Martí‐Fábregas, J., Liu, Y., Uchiyama, S., Mikulík, R., Veltkamp, R. C., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3836 · Cited by 43
Grześk, G., Woźniak-Wiśniewska, A., Błażejewski, J., Górny, B., Wołowiec, Ł., Rogowicz, D., & Nowaczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010282 · Cited by 43
“In contrast, the ENGAGE-AF trial showed that the edoxaban dose of 60 mg increased and the dose of 30 mg reduced the risk of serious gastrointestinal bleeding [72].”
MethodCamm, A. J., Fox, K. A. A., & Peterson, E. D. (2017) · EP Europace · doi:10.1093/europace/eux086 · Cited by 42
Park, J., Shim, J., Lee, J., Park, J., Heo, J., Chang, Y., Song, T., Kim, D., Lee, H. A., Yu, H. T., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023391 · Cited by 42
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Cross, B., Turner, R. M., Zhang, E. J., & Pirmohamed, M. (2024) · The Pharmacogenomics Journal · doi:10.1038/s41397-024-00329-y · Cited by 45
“ENGAGE-AF-TIMI 48 [48] trial demonstrated patients with AF receiving clinical based warfarin dosing who were deemed sensitive and highly sensitive responders to warfarin on genetic testing (incorporating CYP2C9 (*2 and *3 alleles; rs1799853 and rs1057910) and VKORC1 (-1639G->A; rs9923231)) were…”
Oliva, A., Ioppolo, A. M., Chiarito, M., Cremonesi, A., Azzano, A., Miccichè, E., Mangiameli, A., Ariano, F., Ferrante, G., Reimers, B., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034815 · Cited by 42
Philippart, R., Brunet-Bernard, A., Clémenty, N., Bourguignon, T., Mirza, A., Angoulvant, D., Babuty, D., Lip, G. Y. H., & Fauchier, L. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0007 · Cited by 42
Risk of thromboembolic complications in adult congenital heart disease: A literature review
Karsenty, C., Zhao, A., Marijon, É., & Ladouceur, M. (2018) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2018.04.003 · Cited by 42
Direct oral anticoagulants: a review of common medication errors
Barr, D., & Epps, Q. J. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1752-9 · Cited by 43
Ichikawa, H., Shimada, M., Narita, M., Narita, I., Kimura, Y., Tanaka, Μ., Osanai, T., Okumura, K., & Tomita, H. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012195 · Cited by 43
“of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).(30,32,33) In the ROCKET AF (An”
BackgroundMalik, A. H., Yandrapalli, S., Aronow, W. S., Panza, J. A., & Cooper, H. A. (2019) · Heart · doi:10.1136/heartjnl-2019-314767 · Cited by 42
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
VASCERN-HHT, Shovlin, C. L., Millar, C. M., Droege, F., Kjeldsen, A. D., Manfredi, G., Suppressa, P., Ugolini, S., Coote, N., Fialla, A. D., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1179-1 · Cited by 42
Brouwer, T. F., Whang, W., Kuroki, K., Halperin, J. L., & Reddy, V. Y. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013525 · Cited by 41
Miao, B., Sood, N. A., Bunz, T. J., & Coleman, C. I. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13383 · Cited by 42
Lu, G., Conley, P. B., Leeds, J. M., Karbarz, M. J., Levy, G. G., Mathur, V. S., Castillo, J., Crowther, M. A., & Curnutte, J. T. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000885 · Cited by 42
Magnocavallo, M., Bellasi, A., Mariani, M., Fusaro, M., Ravera, M., Paoletti, E., Iorio, B. D. D., Bàrbera, V., Rocca, D. D., Palumbo, R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010083 · Cited by 39
Kubitza, D., Berkowitz, S. D., & Misselwitz, F. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616631427 · Cited by 47
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?
Chan, N., Sager, P. T., Lawrence, J., Ortel, T., Reilly, P. A., Berkowitz, S. D., Kubitza, D., Eikelboom, J. W., Florian, J. A., Stockbridge, N., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.002 · Cited by 41
Al‐Khatib, S. M. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202307180 · Cited by 41
Shimada, Y. J., Yamashita, T., Koretsune, Y., Kimura, T., Abe, K., Sasaki, S., Mercuri, M. F., Ruff, C. T., & Giugliano, R. P. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0574 · Cited by 41
Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects
Dempfle, C.-E. H. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.005 · Cited by 41
Lewalter, T., Kanagaratnam, P., Schmidt, B., Rosenqvist, M., Nielsen‐Kudsk, J. E., Ibrahim, R., Albers, B., & Camm, A. J. (2014) · EP Europace · doi:10.1093/europace/euu069 · Cited by 41
Korenstra, J., Wijtvliet, P., Veeger, N. J. G. M., Geluk, C. A., Bartels, G. L., Posma, J. L., Piersma-Wichers, M. G., Gelder, I. C. V., Rienstra, M., & Tieleman, R. G. (2016) · EP Europace · doi:10.1093/europace/euv397 · Cited by 41
The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review
Li, X., Tse, V. C., Au-Doung, P. L. W., Wong, I. C. K., & Chan, E. W. (2016) · EP Europace · doi:10.1093/europace/euw093 · Cited by 41
Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
Turpie, A. G. G., Purdham, D. M., & Ciaccia, A. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717714921 · Cited by 41
Kim, H., Kim, T., Cha, M., Lee, J., Park, J., Park, J., Kang, K., Shim, J., Uhm, J., Kim, J., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0146 · Cited by 41
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 44
“In a trial of VTE prophylaxis in the medically ill, apixaban did not meet the criteria for superiority versus enoxaparin and had more bleeding [17].”
BackgroundOral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation
Hu, A. H., Niu, J., & Winkelmayer, W. C. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.08.006 · Cited by 42
Progress in the monitoring of direct oral anticoagulant therapy
Patel, J. P., Byrne, R., Patel, R., & Arya, R. (2019) · British Journal of Haematology · doi:10.1111/bjh.15756 · Cited by 41
on behalf of the ETNA-AF-Europe investigators, Caterina, R. D., Kelly, P. J., Monteiro, P. F., Deharo, J., de Asmundis, C., de Sá, E. L., Weiss, T. W., Waltenberger, J. L., Steffel, J., et al. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1144-x · Cited by 41
Guo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 40
An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
Mujer, M. T. P., Rai, M. P., Atti, V., Dimaandal, I., Chan, A. S., Shrotriya, S., Gundabolu, K., & Dhakal, P. (2020) · Advances in Hematology · doi:10.1155/2020/7636104 · Cited by 44
“However, a higher dose of edoxaban caused a higher rate of gastrointestinal bleeding compared to warfarin [4].”
Background
Metadata
- Authors
- Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., Grip, L. T., Patel, S. P., Patel, I., Hanyok, J. J., Mercuri, M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University Hospitals Cleveland Medical Center (US)
- McMaster University (CA)
- National Medical Research Center of Cardiology (RU)
- Osaka National Hospital (JP)
- IQVIA (United States) (US)
- Daiichi Sankyo (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-28
- Volume
- 369
- Issue
- 22
- Pages
- 2093-2104
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096246254
- Cited by
- 5,164
- References
- 24
- Citations by year
- 2026: 201 · 2025: 280 · 2024: 344 · 2023: 419 · 2022: 405 · 2021: 469 · 2020: 505 · 2019: 443 · 2018: 487 · 2017: 454 · 2016: 494 · 2015: 378 · 2014: 266 · 2013: 12
- FWCI
- 260.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- AtriCure
- Boston Scientific Corporation
- Medicines Company
- Janssen Scientific Affairs
- Bayer HealthCare
- Eisai
- St. Jude Medical
- Biosense Webster
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- edoxaban, warfarin, atrial fibrillation, direct oral anticoagulants, factor Xa inhibitors, stroke and systemic embolism, major bleeding, non-inferiority, oral anticoagulation, time in therapeutic range, anticoagulant efficacy and safety, once-daily dosing
- MeSH terms
- Adult, Aged, Anticoagulants, Atrial Fibrillation, Cardiovascular Diseases, Double-Blind Method, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyridines, Thiazoles, Warfarin, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
